Intetumumab

Intetumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetintegrin alpha-V
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6468H10008N1744O2006S40
Molar mass145579.81 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Intetumumab is a human monoclonal antibody targeting integrins[1] that was being studied for the treatment of solid tumors.[2]

Intetumumab was developed by Centocor, Inc.

Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[3]

References

  1. Łasiñska I, Mackiewicz J (2019). "Integrins as A New Target for Cancer Treatment". Anti-Cancer Agents in Medicinal Chemistry. 19 (5): 580–586. doi:10.2174/1871520618666181119103413. PMID 30451118. S2CID 53952455.
  2. "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
  3. "Intetumumab". AdisInsight. Retrieved 30 January 2017.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.